The Australian Mohs database, part II - Periocular basal cell carcinoma outcome at 5-year follow-up

Simple item page
dc.contributor.authorMalhotra, R.
dc.contributor.authorHuilgol, S.
dc.contributor.authorHuynh, N.
dc.contributor.authorSelva-Nayagam, D.
dc.date.issued2004
dc.description.abstract<h4>Objective</h4>To report the outcome with 5-year strict follow-up (only cases where 5-year follow-up is available) of all patients with periocular basal cell carcinoma (BCC) treated with Mohs' micrographic surgery (MMS) in Australia between 1993 and 1996.<h4>Design</h4>Prospective, noncomparative, multicenter, interventional case series.<h4>Methods</h4>A prospective series of 819 patients, undergoing MMS for periocular BCC over a 3-year period (1993-1996).<h4>Inclusion criteria</h4>Periocular BCC referred for MMS.<h4>Main outcome measures</h4>Recurrence, site, size, prior occurrence, defect size, histologic subtype, and presence of perineural invasion.<h4>Results</h4>Eight hundred nineteen patients had 257 (54%) lower eyelid, 195 (41%) medial canthus, and 22 (5%) upper eyelid BCCs. The most common histologic subtypes were nodulocystic (43%) and infiltrating (30%) (P = 0.0003). Sixty-eight percent were primary and 32% were recurrent tumors. Five-year follow-ups for cases between 1993 and 1996 were available in 347 (42%) cases. There were 7 recurrences (2.0%; exact 95% confidence interval [CI]: 0.82%-4.1%), 5 of which were at the medial canthus and all of which were previously recurrent, with up to 3 recurrences before MMS. Previous recurrence (P<0.0001), infiltrating (5) or superficial (2) histologic subtype (P = 0.0882), and medial canthal site were the main predictors of recurrence after MMS. There were no recurrences for primary BCC, and the 5-year recurrence for previously recurrent BCC was 7.8% (exact 95% CI: 3.2%-15.4%).<h4>Conclusion</h4>The Australian MMS database is the largest prospective nationwide series of periocular BCC managed by MMS. The strict 5-year recurrence rates of 0% and 7.8% for primary and recurrent tumors, respectively, confirm MMS as the treatment of choice for periocular BCC.
dc.identifier.citationOphthalmology (Rochester, Minn.), 2004; 111(4):631-636
dc.identifier.doi10.1016/j.ophtha.2003.11.004
dc.identifier.issn0161-6420
dc.identifier.issn1549-4713
dc.identifier.orcidHuilgol, S. [0000-0001-6668-1230]
dc.identifier.orcidSelva-Nayagam, D. [0000-0002-2169-5417]
dc.identifier.urihttp://hdl.handle.net/2440/10656
dc.language.isoen
dc.publisherElsevier Science Inc
dc.source.urihttps://doi.org/10.1016/j.ophtha.2003.11.004
dc.subjectHumans
dc.subjectCarcinoma, Basal Cell
dc.subjectEyelid Neoplasms
dc.subjectNeoplasm Invasiveness
dc.subjectNeoplasm Recurrence, Local
dc.subjectTreatment Outcome
dc.subjectMohs Surgery
dc.subjectFollow-Up Studies
dc.subjectProspective Studies
dc.subjectDatabases, Factual
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectAustralia
dc.subjectFemale
dc.subjectMale
dc.titleThe Australian Mohs database, part II - Periocular basal cell carcinoma outcome at 5-year follow-up
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Surgery publications